CEPI vaccine development partner Clover Biopharmaceuticals has today announced that Clover’s COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum) achieved the primary efficacy endpoint and secondary efficacy endpoints in SPECTRA, a global pivotal Phase 2/3 clinical trial. In the trial, SCB-2019 (CpG 1018/Alum) demonstrated significant efficacy against multiple variants of COVID-19, including the globally-dominant Delta variant. SPECTRA was funded by CEPI as part of a $328 million investment to develop and enable equitable access to SCB-2019 (CpG 1018/Alum).
The full announcement is available to read here.
Welcoming the announcement, Dr. Richard Hatchett, CEO of CEPI said: “This very encouraging data demonstrates the favorable safety profile of Clover’s vaccine and its efficacy against multiple variants of SARS-CoV-2 – including the predominant Delta variant – so it will be a crucial addition to our weaponry in the fight against COVID-19. CEPI’s significant early investments have accelerated the clinical development and manufacturing of the vaccine and will enable equitable access to hundreds of millions of doses through COVAX. As a result of CEPI’s partnership with Clover, this vaccine is poised to play a significant role in protecting those most at risk from COVID-19, wherever they are in the world.”
CEPI’s investment and support have been critical to catalyzing the development of SCB-2019 (CpG 1018/Alum) and enabling access to the vaccine. CEPI funding has supported preclinical and clinical testing of the vaccine, in addition to scaling up the manufacturing process. Pending WHO Emergency Use Listing (EUL) Clover will supply up to 414 million doses of the vaccine to the COVAX Facility for equitable distribution.